CA2273288A1 - Traitement ou inhibition de la neutropenie - Google Patents

Traitement ou inhibition de la neutropenie Download PDF

Info

Publication number
CA2273288A1
CA2273288A1 CA002273288A CA2273288A CA2273288A1 CA 2273288 A1 CA2273288 A1 CA 2273288A1 CA 002273288 A CA002273288 A CA 002273288A CA 2273288 A CA2273288 A CA 2273288A CA 2273288 A1 CA2273288 A1 CA 2273288A1
Authority
CA
Canada
Prior art keywords
carbon atoms
alkyl
phenyl
trifluoromethyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002273288A
Other languages
English (en)
Inventor
James Joseph Gibbons
Judy Lucas
Jeremy Ian Levin
Joseph William Epstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2273288A1 publication Critical patent/CA2273288A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Méthode pour traiter ou inhiber la neutropénie, ou pour accélérer la récupération de neutrophiles chez le mammifère présentant une insuffisance de ces derniers. Cette méthode consiste à administrer à ce mammifère une quantité efficace d'un composé ou d'un médicament contenant le composé de la formule (I) dans laquelle R¿1? et R¿2? sont chacun sélectionnés indépendamment dans un groupe constitué de l'hydrogène, d'un alkyl comprenant entre 1 et 6 atomes de carbone, de benzoyle éventuellement substitué, (a), (b), (c), (d), (e), (f) et -(CH¿2?)¿n?-R ou R¿1? et R¿2? sont des groupes méthylène réunis pour former un noyau hétérocyclique saturé comprenant 4 à 7 chaînons; R est hydroxy, 4-morpholinyle, 1H-imidazol-1-yl, -CH(alkoxy à 1-6 atomes de carbone)¿2?, .alpha.-hydroxybenzyle ou phényle éventuellement substitué; R¿3? est l'hydrogène ou l'alkyle; R¿4? est l'hydrogène, halogène, alkyle, alkoxy ou trifluorométhyle; R¿5? est l'hydrogène ou l'alkyle; et n=1-3, ou un sel pharmaceutiquement acceptable de ce composé.
CA002273288A 1996-12-19 1997-12-17 Traitement ou inhibition de la neutropenie Abandoned CA2273288A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77074396A 1996-12-19 1996-12-19
US08/770,743 1996-12-19
PCT/US1997/023419 WO1998026781A1 (fr) 1996-12-19 1997-12-17 Traitement ou inhibition de la neutropenie

Publications (1)

Publication Number Publication Date
CA2273288A1 true CA2273288A1 (fr) 1998-06-25

Family

ID=25089545

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002273288A Abandoned CA2273288A1 (fr) 1996-12-19 1997-12-17 Traitement ou inhibition de la neutropenie

Country Status (7)

Country Link
EP (1) EP0957918A1 (fr)
JP (1) JP2001506998A (fr)
AR (1) AR010808A1 (fr)
AU (1) AU5611398A (fr)
CA (1) CA2273288A1 (fr)
WO (1) WO1998026781A1 (fr)
ZA (1) ZA9711342B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2650962C2 (ru) * 2012-06-07 2018-04-18 Чилдрен'З Хоспитал Лос Анджелес Способы лечения нейтропении с применением ретиноидных агонистов
EP3107533A4 (fr) 2014-02-18 2017-10-18 Children's Hospital Los Angeles Compositions et méthodes de traitement de la neutropénie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2615291B1 (fr) * 1987-05-15 1989-07-13 Thomson Csf Procede de test en fonctionnement d'un dispositif de visualisation d'informations radar et mise en oeuvre de ce procede
EP0329940B1 (fr) * 1988-02-22 1994-01-05 American Cyanamid Company 5-(Amino substitué)-8-(phényle ou phényle substitué)-3H,6H-1,4,5a,8a-tétraazaacénaphtylène-3-ones
US4916137A (en) * 1988-02-22 1990-04-10 American Cyanamid Company 5-(Substituted-amino)-8-(phenyl or substituted-phenyl)-3H,6H-1,4,5A,8A-tetraazaacenaphthylen-3-ones and treatment of neural behavior disorders

Also Published As

Publication number Publication date
WO1998026781A1 (fr) 1998-06-25
ZA9711342B (en) 1999-06-17
AR010808A1 (es) 2000-07-12
JP2001506998A (ja) 2001-05-29
EP0957918A1 (fr) 1999-11-24
AU5611398A (en) 1998-07-15

Similar Documents

Publication Publication Date Title
AU2018394996B2 (en) Amino-methyl piperidine derivative as kinase inhibitor
US11464781B2 (en) PDE1 inhibitors for ophthalmic disorders
US6294565B1 (en) Methods of combatting infectious diseases using dicationic bis-benzimidazoles
US9006258B2 (en) Method of treating female sexual dysfunction with a PDE1 inhibitor
JP5810157B2 (ja) プロテインキナーゼ阻害剤および処置の方法
AU2005312061B2 (en) Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof
US20100087450A1 (en) Organic compounds
EP0729758A2 (fr) Pyrazolopyrimidines et pyrrolopyrimidines pour traiter les troubles neuronaux et autres maladies
CA2287122A1 (fr) Traitement de l'hypertrophie benigne de la prostate avec des agents augmentant les concentrations de gmpc
CA2273288A1 (fr) Traitement ou inhibition de la neutropenie
US6051578A (en) Pyrazolopyrimidines for treatment of CNS disorders
US5932585A (en) Method of treating or inhibiting neutropenia
AU2006224623A1 (en) Method for preventing cardiovascular diseases
US20020169154A1 (en) Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
JP2020528052A (ja) がん治療におけるエリブリン及びサイクリン依存的キナーゼ阻害剤の使用
US4916137A (en) 5-(Substituted-amino)-8-(phenyl or substituted-phenyl)-3H,6H-1,4,5A,8A-tetraazaacenaphthylen-3-ones and treatment of neural behavior disorders
NZ297424A (en) Use of an aminopurine derivative to treat latent infection of the herpes virus
WO2014174478A1 (fr) Combinaisons pharmaceutiques d'un inhibiteur de la pkc et d'un inhibiteur du récepteur tyrosine-kinase c-met
JP2641556B2 (ja) 5―(置換アミノ)―8―(フエニルまたは置換フエニル)―3H,6H―1,4,5a,8a―テトラアザアセナフチレン―3―オン
WO1986007537A2 (fr) Compositions pharmaceutiques contenant des azanaphtalenes
US20030087899A1 (en) Novel methods for the treatment and prevention of pain
CA3155068A1 (fr) Combinaison de medicaments contenant un agoniste de tlr7
CA2121613A1 (fr) Compose actif d'une eponge
RU97116717A (ru) 6-замещенные производные пиразоло[3,4-d]пиримидин-4-она, составы на их основе и способы их применения
RU97116586A (ru) 6-арил-пиразоло[3,4-d]пиримидин-4-оны, составы на их основе и способы их применения

Legal Events

Date Code Title Description
FZDE Dead